TY - JOUR
T1 - Aortic Insufficiency During HeartMate 3 Left Ventricular Assist Device Support
AU - IMAMURA, TERUHIKO
AU - NARANG, NIKHIL
AU - KIM, G. E.N.E.
AU - NITTA, DAISUKE
AU - FUJINO, TAKEO
AU - NGUYEN, A. N.N.
AU - GRINSTEIN, JONATHAN
AU - RODGERS, DANIEL
AU - OTA, TAKEYOSHI
AU - JEEVANANDAM, VALLUVAN
AU - SAYER, GABRIEL
AU - URIEL, N. I.R.
N1 - Funding Information:
Disclosures: NU receives grant support from Abbott and Medtronic; GS is a consultant for Medtronic; VJ is a consultant for Abbott.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - Background: Aortic insufficiency (AI) is associated with morbidity and mortality in patients with continuous-flow left ventricular assist devices (LVADs), whereas its impact on the HeartMate 3 LVAD cohorts remains uninvestigated. We aimed to investigate the clinical impact of AI on patients with HeartMate 3 LVADs. Methods and Results: Consecutive 61 patients (median age 54 years; 67% male) implanted with HeartMate 3 LVAD between 2015 and 2019 were enrolled and underwent echocardiography at 3 months after LVAD implantation. AI severity was quantified by the novel Doppler echocardiographic method obtained at the outflow cannula and the calculated regurgitation fraction of 30% or greater (moderate or greater) was defined as significant. At 3 months after implant, 12 patients (20%) had significant AI. They had a higher incidence of death or heart failure readmissions compared with those without significant AI during a 1-year observational period (70% vs 24%, P = .003) with an adjusted hazard ratio of 2.76 (95% confidence interval 1.03–7.88). Conclusions: In patients with HeartMate 3 LVAD support, significant AI remains both prevalent and a clinically significant downstream complication.
AB - Background: Aortic insufficiency (AI) is associated with morbidity and mortality in patients with continuous-flow left ventricular assist devices (LVADs), whereas its impact on the HeartMate 3 LVAD cohorts remains uninvestigated. We aimed to investigate the clinical impact of AI on patients with HeartMate 3 LVADs. Methods and Results: Consecutive 61 patients (median age 54 years; 67% male) implanted with HeartMate 3 LVAD between 2015 and 2019 were enrolled and underwent echocardiography at 3 months after LVAD implantation. AI severity was quantified by the novel Doppler echocardiographic method obtained at the outflow cannula and the calculated regurgitation fraction of 30% or greater (moderate or greater) was defined as significant. At 3 months after implant, 12 patients (20%) had significant AI. They had a higher incidence of death or heart failure readmissions compared with those without significant AI during a 1-year observational period (70% vs 24%, P = .003) with an adjusted hazard ratio of 2.76 (95% confidence interval 1.03–7.88). Conclusions: In patients with HeartMate 3 LVAD support, significant AI remains both prevalent and a clinically significant downstream complication.
UR - http://www.scopus.com/inward/record.url?scp=85086713807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086713807&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2020.05.013
DO - 10.1016/j.cardfail.2020.05.013
M3 - Article
C2 - 32473380
AN - SCOPUS:85086713807
SN - 1071-9164
VL - 26
SP - 863
EP - 869
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 10
ER -